Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

This is a clinical trial protocol describing the VAC 060 study, undertaken by the Jenner Institute, sponsored by the University of Oxford. It was funded by a Strategic Primer grant award from the European and Developing Countries Clinical Trials Partnership (EDCTP) with co-funding from Swedish International Development Cooperation Agency (Sida); UK Medical Research Council; Irish Aid, Department of Foreign Affairs and Trade, Ireland;and Bundesministerium für Bildung und Forschung (BMBF), Germany and was performed by the Malaria Vectored Vaccines Consortium 2 (MVVC 2) (EDCTP, grant number SP.2011.41304.025). The European Vaccine Initiative (EVI) coordinated the EDCTP-funded MVVC 2 project. The work was also supported by the UK National Institute of Health Research through the Oxford Biomedical Research Centre ( (A91301 Adult Vaccine) and the Wellcome Trust (https://www. (084113/Z/07/Z).

Original publication






University of Oxford

Publication Date